Real-World Evidence Study of Decision Support in MS Care
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study helps doctors decide on the best MS treatment for you using an AI decision-support tool. You'll be part of a real-world evaluation of how this tool works when doctors are considering changing your MS medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 50 years old
- Diagnosed with relapsing-remitting MS (the most common type)
- Your doctor is considering a change in your MS treatment
- Recent brain MRI scans (within 6 months) available for the study
- Able to give written consent and follow study guidelines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
This study observes people with multiple sclerosis (MS) to collect health data and samples over time. It aims to use digital tools and artificial intelligence to better understand the disease and improve care.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Hear when a new Relapsing - Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.